US5321012A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
Assignee: Virginia Commonwealth University
•
Filing: 1993-04-06
•
Granted: 1994-06-14
•
Expires: 2013-04-06
Abstract
Abstract Nontoxic substances that block the N-methyl-D-aspartate (NMDA) receptor, e.g., a morphinan such as dextromethorphan or dextrorphan, or that block a major intracellular consequence of NMDA receptor activation, e.g., a ganglioside such as GM 1 or GT 1b , a phenothiazine such as trifluoperazine or a naphthalenesulfonamide such as N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, inhibit the development of tolerance to and/or dependence on addictive drugs, e.g., narcotic analgesics such as morphine, codeine, etc.
Inventors
- 👤 David J. Mayer
- 👤 Donald D. Price
- 👤 Jianren Mao
- 👤 John W. Lyle
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 05:00
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/47; A61K31/485; A61K31/54; A61P; A61P25/00; A61P25/04; A61P25/20; A61P25/24; A61P25/26; A61P25/30; A61P25/36; A61P43/00
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
47 words
A composition comprising a narcotic analgesic and at least one nontoxic substance that inhibits the development of tolerance to and/or dependence on the narcotic analgesic, said nontoxic substance being selected from the group consisting of dextromethorphan, dextrorphan, trifluoperazine, N-(6-aminohexyl)-5-chloro-1-naphthalene sulfonamide, their mixtures and their pharmaceutically acceptable salts.
Claim 2
Dependent Claim
47 words
A composition comprising a narcotic analgesic and at least one nontoxic substance that inhibits the development of tolerance to and/or dependence on the narcotic analgesic, said nontoxic substance being selected from the group consisting of dextromethorphan, dextrorphan, trifluoperazine, N-(6-aminohexyl)-5-chloro-1-naphthalene sulfonamide, their mixtures and their pharmaceutically acceptable salts.
Claim 3
Dependent Claim
65 words
The composition of claim 1 wherein the narcotic analgesic is selected from the group consisting of alfentanyl, alphaprodine, anileridine, bezitramide, codeine, dihydrocodeine, diphenoxylate, ethylmorphine, fentanyl, heroin, hydrocodone, hydromorphone, isomethadone, levomethorphan, levorphanol, metazocine, methadone, metopon, morphine, opium extracts, opium fluid extracts, powdered opium, granulated opium, raw opium, tincture of opium, oxycodone, oxymorphone, pethidine, phenazocine, piminodine, racemethorphan, racemorphan, thebaine, their mixtures and their pharmaceutically acceptable salts thereof.
Claim 4
Dependent Claim
10 words
The composition of claim 1 in sustained release dosage form.
Claim 5
Dependent Claim
38 words
The composition of claim 1 wherein the nontoxic substance that inhibits the development of tolerance to and/or dependence on the narcotic analgesic is selected from the group consisting of dextromethorphan, dextrorphan, their mixtures and their pharmaceutically acceptable salts.
Claim 6
Dependent Claim
29 words
The composition of claim 4 wherein the narcotic analgesic is selected from the group consisting of codeine, fentanyl, heroin, hydrocodone, morphine, oxycodone, their mixtures and their pharmaceutically acceptable salts.
Claim 7
Dependent Claim
29 words
The composition of claim 5 wherein the narcotic analgesic is selected from the group consisting of codeine, fentanyl, heroin, hydrocodone, morphine, oxycodone, their mixtures and their pharmaceutically acceptable salts.
Claim 8
Independent Claim
89 words
A method of inhibiting the development of tolerance to and/or dependence on a narcotic analgesic administered to a mammal which is liable to addiction thereto which comprises administering the narcotic analgesic to the mammal before, with or following administration to the mammal of a tolerance-reducing and/or dependence-reducing amount of at least one nontoxic substance that inhibits the development of tolerance to and/or dependence on the narcotic analgesic, said nontoxic substance being selected from the group consisting of dextromethorphan, dextrorphan, trifluoperazine, N-(6-aminohexyl)-5-chloro-1-naphthalene sulfonamide, their mixtures and their pharmaceutically acceptable salts.
Claim 9
Independent Claim
89 words
A method of inhibiting the development of tolerance to and/or dependence on a narcotic analgesic administered to a mammal which is liable to addiction thereto which comprises administering the narcotic analgesic to the mammal before, with or following administration to the mammal of a tolerance-reducing and/or dependence-reducing amount of at least one nontoxic substance that inhibits the development of tolerance to and/or dependence on the narcotic analgesic, said nontoxic substance being selected from the group consisting of dextromethorphan, dextrorphan, trifluoperazine, N-(6-aminohexyl)-5-chloro-1-naphthalene sulfonamide, their mixtures and their pharmaceutically acceptable salts.
Claim 10
Dependent Claim
65 words
The method of claim 7 wherein the narcotic analgesic is selected from the group consisting of alfentanyl, alphaprodine, anileridine, bezitramide, codeine, dihydrocodeine, diphenoxylate, ethylmorphine, fentanyl, heroin, hydrocodone, hydromorphone, isomethadone, levomethorphan, levorphanol, metazocine, methadone, metopon, morphine, opium extracts, opium fluid extracts, powdered opium, granulated opium, raw opium, tincture of opium, oxycodone, oxymorphone, pethidine, phenazocine, piminodine, racemethorphan, racemorphan, thebaine, their mixtures and their pharmaceutically acceptable salts thereof.
Claim 11
Dependent Claim
38 words
The method of claim 7 wherein the nontoxic substance that inhibits the development of tolerance to and/or dependence on the narcotic analgesic is selected from the group consisting of dextromethorphan, dextrorphan, their mixtures and their pharmaceutically acceptable salts.
References Cited (Backward Citations)
US2770569A
Cited
US4126684A
Cited
US4416871A
Cited
US4362870A
Cited
US4316888A
Cited
US4464378A
Cited
US4446140A
Cited
US4476141A
Cited
US5034395A
Cited
US5137889A
Cited
US4834965A
Cited
US4788055A
Cited
US4888347A
Cited
US4758559A
Cited
US4828836A
Cited
US4834985A
Cited
US4816264A
Cited
US5145842A
Cited
US5093525A
Cited
US4906779A
Cited
US4937232A
Cited
US4816450A
Cited
US4806543A
Cited
US5047229A
Cited
US4959493A
Cited
US4919916A
Cited
US4912114A
Cited
US5041446A
Cited
US5185329A
Cited
US4990519A
Cited
US4996047A
Cited
US5071646A
Cited
US4994446A
Cited
US5093129A
Cited
US4942182A
Cited
US4924008A
Cited
US5133974A
Cited
US4994467A
Cited
US5190925A
Cited
US4975430A
Cited
US5124340A
Cited
US5028611A
Cited
US5034400A
Cited
US5028707A
Cited
US5013540A
Cited
US5075341A
Cited
US5051426A
Cited
US5095009A
Cited
US5051442A
Cited
US5057519A
Cited
US5183807A
Cited
US5106847A
Cited
US5171752A
Cited
US5091391A
Cited
US5109017A
Cited
US5141957A
Cited
US5137919A
Cited
US5151360A
Cited
US5118675A
Cited
US5124319A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-06-13 | 1997-12-13 | 1998-06-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-06-13 | 2001-12-13 | 2002-06-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-06-13 | 2005-12-13 | 2006-06-14 | $7700.00 | Window Closed / Lapsed |